Turnstone Biologics — Investor Presentation (March 2024)
28 slides from Turnstone Biologics's investor presentation, Mar 5, 2024
Slide 1: Corporate Presentation March 2024
Corporate Presentation March 2024 Nasdaq: TSBX Non-Confidential Exhibit 99.1
Slide 2: Forward-looking statements disclaimer
This presentation and any accompanying oral commentary have been prepared by Turnstone Biologics Corp. (“Turnstone”) for informational purposes only and not for any other purpose. All statements contained in this presentation and the accompanying oral commentary, other than statements of historical
Slide 3: Turnstone is Pioneering Advancements in Selected TIL Therapy
Turnstone is Pioneering Advancements in Selected TIL Therapy Next-Generation Therapy Designed to Treat and Cure Solid Tumors OUR MISSION Profoundly transform the treatment paradigm for patients with a broad range of solid tumors with next-generation TIL therapies that overcome the limitations of cur
Slide 4: Solid Tumors Represent a Serious Unmet Medical Need
Solid Tumors Represent a Serious Unmet Medical Need Approximately 90% of all new cancers per year are solid tumors 1National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER), accessed March 2024; 2Cancer Metastasis: Guan X. Cancer Metastases: Challenges and Opportunities. Acta P
Slide 5: Indication Spotlight: Colorectal Cancer (CRC)
Indication Spotlight: Colorectal Cancer (CRC) 2nd Leading Cause of U.S. Cancer Deaths1 3rd 153K 53K most commonly diagnosed cancer2 expected new cases this year3 number of deaths expected in 20244 Difficult-To-Treat Tumor Unresponsive To Most Immune-Based Therapies Immunologically “cold” tumor chara
Slide 6: Turnstone is Pioneering Advancements in Selected TIL Therapy
Turnstone is Pioneering Advancements in Selected TIL Therapy Next-generation therapy designed to treat and cure solid tumors Differentiated approach centered around tumor-reactive T cell selection (Selected TILs) Lead asset, TIDAL-01, being evaluated in multiple Phase 1 studies with initial clinical
Slide 7: Management team
Sammy Farah, MBA, PhD Chief Executive Officer Vijay Chiruvolu, MBA, PhD Interim Chief Technology Officer Venkat Ramanan, PhD Chief Financial Officer Stewart Abbot, PhD Chief Scientific Officer Saryah Azmat Chief Business Officer Mike Burgess, MBChB, PhD Interim Chief Medical Officer 20+ years of sci
Slide 8: Distinguished Advisors and Key Collaborators
Distinguished Advisors Key Collaborators Simon Turcotte, MD, MSc Associate Professor of Surgery; Lead of Adoptive T Cell Cancer Immunotherapy Program, University of Montreal Hospital Research Centre (CRCHUM) James Mulé, PhD Associate Center Director of Translational Science Moffitt Cancer Center Ste
Slide 9: Turnstone Pipeline
Turnstone Pipeline Opportunity to address broad set of solid tumor patient populations Product Overview Program Key Indications Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Selected TILs TIDAL-01 TIDAL-02 Initial clinical data in mid-2024 IND submission IND submission Tumor-reactiv
Slide 10: Selected TILs and TIDAL-01
SELECTED TILs AND TIDAL-01 Corporate Presentation | March 2024
Slide 11: Expanding the Frontiers of TIL Therapy
Expanding the Frontiers of TIL Therapy Building upon first-to-market TIL therapy to deliver differentiated product with unique market opportunity Turnstone is developing the Next-Generation of TIL Therapies First approval for a TIL therapy brings new option for solid tumors Amtagvi is the first and
Slide 12: Selected TILs Have Potential for More Targeted Tumor Killing
Next-generation TIL therapy based on isolation, selection and expansion of tumor-reactive T cells to improve product potency¹ Designed to address a broad range of solid tumor types Selected TILs Selected TILs Have Potential for More Targeted Tumor Killing Starting materials for solid tumors typicall
Slide 13: Selected TILs Are Based on Advances from Academia
Early academics working on first-generation TILs led to development of a leading Bulk TIL company’s current process Success to date has been limited to melanoma Bulk TILs Melanoma Sheba, NCI, Moffitt, MD Anderson Melanoma Bulk TIL leading competitor clinical development initiation Cervical NCI Melan
Slide 14: Academic clinical evidence for selected TILs
*7 patients received TIL product with confirmed tumor-specific reactivity out of 13 patients who were evaluable for clinical response †6 patients enrolled on adoptive cell transfer protocol of enriched neoantigen-specific TIL out of 28 patients who contained TIL that recognized at least one immunoge
Slide 15: TIDAL-01 Process
Tumor sequencing to identify all possible tumor mutations (antigens) Synthesize the tumor mutations in the form of long peptides Pulse patient-derived dendritic cells with the synthesized tumor antigens for natural processing and presentation Incubate TILs with presented tumor antigens and select tu
Slide 16: TIDAL-01 product consists of diverse T cells with confirmed tumor-reactivity
TIDAL-01 product consists of diverse set of T cells with confirmed tumor-reactivity (TCRs) Selected tumor-reactive T cells are typically found in only very low frequencies in Bulk TILs These TCRs within Selected TILs deliver higher frequency of immunostimulatory cytokine expression in CD4+ and CD8+
Slide 17: TIDAL-01 Displays Higher Capacity to Kill Tumor Cells
TIDAL-01 Displays Higher Capacity to Kill Tumor Cells Melanoma Patient Sample Time: 0 Time: 2 Days TIDAL-01 Selected TILs Bystander Cells Tumor Only Effector to target ratio: 1:2 Tumor Cells T Cells Dead Cells (CAS3/7)
Slide 18: TIDAL-01 Clinical Development
TIDAL-01 CLINICAL DEVELOPMENT Corporate Presentation | March 2024
Slide 19: TIDAL-01 Phase 1 Clinical Trials in Advanced Solid Tumors
TIDAL-01 Phase 1 Clinical Trials in Advanced Solid Tumors Demonstrate the safety, biology, initial efficacy and manufacturing feasibility of TIDAL-01 in a Phase 1, first-in-human, non-randomized, open-label, single-dose study in patients with advanced solid tumors Objective Structure Turnstone spons
Slide 20: TIDAL-01 Phase 1 Study is Actively Enrolling Patients
TIDAL-01 Phase 1 Study is Actively Enrolling Patients Phase 1 Study Design TIL Manufacturing IL-2 ± a-PD-1* TIDAL-01 TIL Lymphodepletion Cy-Flu TIL Harvest & Apheresis *a-PD1 combination in STARLING clinical trial and in HNSCC and CRC under Moffitt ISTs; Patients will also be receiving pembrolizumab
Slide 21: TIDAL-01 Indication Focus on Multiple Solid Tumors
TIDAL-01 Phase 1 Indication Focus on Multiple Solid Tumors with Critical Unmet Need With approximately 539K new cases1 and 107K deaths2 in the U.S. annually, Turnstone is targeting indications with serious disease burdens Multiple high-value targets allow for exploration with FIH therapy (some of wh
Slide 22: Indication Spotlight: Colorectal Cancer
1NCCN Guidelines Version 4.2023; BRAFTOVI Prescribing Information; Erbitux Prescribing Information; Daiichi-Sankyo Press Release Aug 2023 (Enhertu BTD); JCO 40, 119-119(2022) (DESTINY-CRC01), Ann Surg Oncol. 2008 Sep;15(9):2388-94; Cancer Med. 2020 Feb; 9(3): 1044–1057; Onco Targets Ther. 2020 Dec 8
Slide 23: Manufacturing Highlights
Manufacturing Highlights Moffitt Cell Therapy Facility to support investigator sponsored trials and Charles River Laboratories to support the STARLING trial Turnstone intends to demonstrate the benefit of TIDAL-01 in solid tumors where objective response and/or durability of Bulk TILs has not been e
Slide 24: Emerging Portfolio and Competitive Profile
EMERGING PORTFOLIO AND COMPETITIVE PROFILE Corporate Presentation | March 2024
Slide 25: Emerging Pipeline with Significant Upside Potential
Emerging Pipeline with Significant Upside Potential Selected TILs + Virus TIDAL-02 Selected TILs with next-generation manufacturing and TIL functional and quality enhancements Viral immunotherapy pre-treatment and post- treatment in combination with TIDAL-01 Turnstone is building a TIL pipeline to f
Slide 26: Turnstone Competitive Positioning
Standard Bulk TILs Modified Bulk TILs Bulk TILs + Genetic Engineering Bulk TILs + Neoantigen Enrichment Bulk TILs + Culture Enhancements Turnstone Competitive Positioning Isolation and expansion of all TILs in the tumor Selected TILs Turnstone is pioneering advancements in Selected TIL Therapy Turns
Slide 27: Turnstone Biologics Highlights
Turnstone Biologics Highlights Initial clinical update from Phase 1 TIDAL-01 studies anticipated in mid-2024 TILs have been recently approved by the FDA for the treatment of cutaneous melanoma Academic studies provide early clinical evidence for next-generation selected TIL approach in multiple soli
Slide 28: Thank You
Non-Confidential Thank You
Turnstone Biologics — Investor Presentation (March 2024) on 6ix